Figure 2. A, Concentrations of plasma mature BNP levels at baseline and at 40, 80, 120, and 180 minutes after the start of saline infusion. Solid line with squares represents pre‐bypass surgery subjects and dotted line with triangles represents post‐bypass surgery subjects. B, Concentrations of plasma Nt‐proBNP levels at baseline and at 40, 80, 120, and 180 minutes after the start of saline infusion. Solid line with squares represents pre‐bypass surgery subjects and dotted line with triangles represents post‐bypass surgery subjects. BNP indicates B‐type natriuretic peptide; Nt‐proBNP, N‐terminal pro‐BNP.

"A doctor is much more likely to prescribe a drug that addresses the underlying metabolic problem," Dr Belyea said. In addition, all of the drugs currently on the market have noticeable side-effects ranging from mood changes to unpleasant effects on the digestive system. The FDA withdrew fenfluramine and dexfenfluramine (Redux), from the market in 1997 after the drugs were linked to heart valve abnormalities.
As simple and basic as it is, eating less calories is much harder in practice than it sounds. Ask anyone who has ever gone on a diet before! Everyone knows if you want to lose weight, you need to eat less. It’s the first step of any legitimate diet and fitness program, but how much less, and what to eat remains a mystery to many dieters. Or, the results don’t come quickly enough and the dieter gives up before real results are experienced.
The levels of plasma glycerol were determined according to the method previously described (8) and expressed as a change from d 0 values. The amount of glycerol present in the plasma was enzymatically assayed using glycerol phosphate oxidase reactions (catalog no. GPO-337, Sigma Diagnostics, St. Louis, MO). Plasma glycerol was determined using a spectrophotometer and converted to micromoles per deciliter.
There are several limitations of our study. Given the nature of our physiologic protocols, which required two large volume saline infusions in obese patients before and after surgery, our sample size was modest. Nonetheless, we were able to elicit significant relationships of all four natriuretic peptides (ANP, Nt‐proANP, BNP, and Nt‐proBNP) across a variety of salt conditions before and after surgical weight loss. Our study population consisted of primarily females. We do not believe from prior epidemiologic studies looking at resting natriuretic peptide levels in obese individuals12 that having more men in our cohort would have modified our findings. Prior epidemiologic studies do not suggest that gender modifies the association between obesity and natriuretic peptide concentrations. We did not examine short‐term changes in the natriuretic peptide system, as a physiologic assessment immediately after surgery would have been impractical and potentially confounded by post‐operative shifts in volume or nutrition. We also focused on surgical weight loss because weight loss with non‐surgical treatments is less consistent. Thus, we cannot exclude any surgery‐specific effects. Because the saline infusion was indexed to BSA, less saline was given at the post‐weight loss visit. This could have created a “conservative” bias, eg, toward observing a smaller natriuretic peptide response after surgery. Indexing was performed to ensure that the amount of saline relative to plasma volume was relatively constant. Lastly, we did not perform a complete assessment of the renin‐angiotensin‐aldosterone system and the sympathetic nervous system, all of which could also be primarily affected resulting in the observed responses of the natriuretic peptide system after weight loss and/or saline loading.

Like everything in life, you need to be careful. Too much of a good thing can be bad. Water and oxygen are essential for survival, however in excessive amounts be prepared to have ‘000’ on standby. The same principal is true for any drug or peptide. When used at the recommended dose, clinical trials have proven peptides to be effective with minimal side effects, if any. In addition, the body even has its own natural feedback mechanisms in place to downregulate high levels.

The ACMS recommended that Growth Hormone Releasing Hormones (GHRHs), Growth Hormone Secretagogues (GHSs), Growth Hormone Releasing Peptides (GHRPs) as well as new individual substance entries for CJC-1295, ipamorelin, pralmorelin (Growth Hormone Releasing Peptide-2), Growth Hormone Releasing Peptide-6, hexarelin and AOD-9604 be included in Schedule 4.


The final study involved an assessment of the acute effect of AOD9604 and a β3-AR agonist (BRL37344) on energy expenditure, fat oxidation, and glucose oxidation in WT andβ 3-KO mice. When AOD9604 or BRL37344 were administered to WT mice, an acute increase in fat oxidation and energy expenditure occurred, with an associated reduction in glucose oxidation (Fig. 6A). The effect plateaued 18 min following injection and remained stable for the duration of the experiment. The response to the two compounds was very similar, despite the fact we have previously shown that AOD9604 does not directly interact with the β3-AR as demonstrated by ligand binding studies (11). This clear separation of pathways was further confirmed in Fig. 6B in which AOD9604 clearly increases fat oxidation and energy expenditure inβ 3-KO mice, whereas BRL37344 does not. The KO mice neither decrease their glucose oxidation in response to AOD9604 nor show a prolonged increase in fat oxidation and energy expenditure in response to AOD9604.

The scheduling of paracetamol and caffeine when combined in a compound analgesic as the only two active ingredients was amended from Schedule 4 to Schedule 2 by the NDPSC at its 50th Meeting in June 2007. Evidence reviewed by the Committee at that time conclusively demonstrated that the key ingredient in terms of analgesic overuse and nephropathy was phenacetin and not caffeine. It was agreed that the indications for use, safety profile and potential for misuse met the criteria for a Schedule 2 medicine.


These results also demonstrate that, unlike hGH, AOD9604 has no negative effect on carbohydrate metabolism. This was previously demonstrated in mice. Chronic administration of hGH to ob/ob mice depressed glucose oxidation and increase plasma glucose levels. AOD9604 had no such effects, no changes in circulating plasma glucose in either lean nor obese ob/ob mice have been observed [20]. AOD9604 did not cause hyperglycemia or affect insulin sensitivity in rats and mice [18, 20].
I have been using sermorelin (bioidentical growth hormone releasing hormone) for 2 months now to help heal a nasty right quad tendon rupture suffered the end of December. I’m 52 years old with 7% bodyfat and am a lifetime strength trainer and former high level bike racer. 2 months ago, in spite of months of religious rehab, I couldn’t do a single right leg bench stepup. Yesterday I was doing 20lb DB’s for repeated sets of 15. I get complete blood panels every 6 months, and my last labs in May showed my IGF-1 levels off the reference range low. I get my next bloods in a couple of weeks. I was initially afraid to try this hormone due to the cancer implications, and I didn’t need it to be lean and fit, but I was desperate and for my injury recovery, and it has made a significant difference. Plus, I believed supplementing the releasing hormone vs, IGF-1 limits the possibility of increasing the levels too much, as well as causing a negative feedback loop. By the way, I also tried TB-500 previous to the sermorelin, and it seemed to make some other achy joints in the gym go away, but didn’t seem to help the quad injury.

CJC1295 is a 30 amino acid peptide, which primarily functions as a growth hormone releasing hormone analogue (mimicking the effect of GHRH). It was initially invented to treat deep fat deposits in people, because it is known that having an increase in our own growth hormone levels will target this. It stimulates production of our own growth hormone from the pituitary gland.
There were no significant changes in IGF-1 values observed during 24 hours following any AOD9604 dose compared with placebo. No significant differences in glucose levels were observed following AOD9604 administration compared with placebo with the exception of one isolated time point (8% increase 12 hour post treatment in one subject receiving 54 mg AOD09604). There were no clinically significant observable trends in vital signs, physical examinations, abnormalities noted in the ECG measurements, or findings in the safety-related laboratory tests throughout the study.
A comparison of β3-AR RT-PCR expression levels in white (A) and brown (B) adipose tissues from lean and obese mice treated for 14 d with saline, AOD9604, or hGH. Results are displayed as a percentage, compared with lean controls, and expressed as the mean ± SE of three determinations in each group. *, P < 0.05; #, P< 0.05 obese control vs. lean control.

Tβ4 has been used at our clinic with a great deal of success in patients suffering from Lyme disease or other infectious and/or inflammatory conditions. Tβ4 is very well tolerated and has not been found to cause any significant side effects. It can be taken on its own or in conjunction with an existing therapy, making it a versatile and valuable drug.
Another side effect of the CJC-1295 is acromegaly, since it helps in increasing the levels of the growth hormone. Acromegaly is a condition where extra growth hormone is released even after the internal organs and the skeleton have finished growing. This causes thickening of the skin, deepening of voice, enlargement of jaws, and slurring of speech. Another effect of acromegaly is the swelling of the soft tissue in the internal organs. This could result in the weakening of the muscles of the internal organs, like the heart. This was tested during the phase 2 testing of CJC-1295.
Peptide therapy encompasses numerous different drugs with varied effects, ranging from immune modulation and tissue repair to fat loss and muscle building. Our center has seen very positive results in patients with CFS, Hashimoto’s thyroiditis, Lyme disease, and fibromyalgia, among other conditions. Ask your physician or speak to a patient representative at (877) 508-1177 to find out if peptide therapy is right for you.
Collagen is also supposed to help with joint pain. Although I (luckily) don’t have chronic pain in my joints, my knees do flare up from time to time ever since I ran a half marathon a couple years ago. I also get some soreness in what feels like the bones in my legs a couple times a week, usually after a run or intense cardio session. If drinking collagen would ease this pain, then I was game.
The secret to health and wellness has been revealed. Recent scientific developments and studies have confirmed that the use of peptide supplements under the careful supervision of hormone doctors, will help to deliver your body to a state of youthful proportion and function. Through peptide supplementation, you enable the body to regenerate, enhance and perform to its optimal level.
×